BACKGROUND: Artemisinin-based combination therapies (ACTs) have significantly contributed to reduce Plasmodium falciparum malaria burden in Vietnam, but their efficacy is challenged by treatment failure of dihydroartemisinin/piperaquine ACT in Southern provinces. OBJECTIVES: To assess the efficacy of dihydroartemisinin/piperaquine for uncomplicated P. falciparum malaria in Gia Lai, Central Vietnam, and determine parasite resistance to artemisinin (ClinicalTrials.gov identifier NCT02604966). METHODS: Sixty patients received either dihydroartemisinin/piperaquine (4 mg/kg/day, 3 days; n = 33) or artesunate monotherapy (4 mg/kg/day, 3 days; n = 27) followed by dihydroartemisinin/piperaquine (AS + DHA/PPQ). Clinical phenotypes were determined during a 42 day follow-up and analysed together with ex vivo susceptibility to antimalarials and molecular markers of drug resistance. RESULTS: Day 3 positivity rate was significantly higher in the AS + DHA/PPQ arm compared with dihydroartemisinin/piperaquine (70.4% versus 39.4%, P = 0.016). Parasite clearance time was 95.2 h (AS + DHA/PPQ) versus 71.9 h (dihydroartemisinin/piperaquine, P = 0.063) and parasite clearance half-life was 7.4 h (AS + DHA/PPQ) versus 7.0 h (dihydroartemisinin/piperaquine, P = 0.140). Adequate clinical and parasitological response at Day 42 was 100% in both arms. By RT-qPCR, 36% (19/53) patients remained positive until Day 7. No recurrences were detected. kelch13 artemisinin resistance mutations were found in 87% (39/45) of isolates and 50% (20/40) were KEL1/C580Y. The piperaquine resistance marker plasmepsin-2 was duplicated in 10.4% (5/48). Isolates from Day 3-positive patients (n = 18) had higher ex vivo survival rates to artemisinin compounds (P < 0.048) and prevalence of kelch13 mutations (P = 0.005) than Day 3-negative patients (n = 5). The WHO definition of artemisinin resistance was fulfilled in 60% (24/40) of cases. CONCLUSIONS: Although dihydroartemisinin/piperaquine remained effective to treat P. falciparum, the high Day 3 positivity rate and prevalence of KEL1 strains calls for continuous monitoring of dihydroartemisinin/piperaquine efficacy in Central Vietnam.
BACKGROUND:Artemisinin-based combination therapies (ACTs) have significantly contributed to reduce Plasmodium falciparum malaria burden in Vietnam, but their efficacy is challenged by treatment failure of dihydroartemisinin/piperaquine ACT in Southern provinces. OBJECTIVES: To assess the efficacy of dihydroartemisinin/piperaquine for uncomplicated P. falciparum malaria in Gia Lai, Central Vietnam, and determine parasite resistance to artemisinin (ClinicalTrials.gov identifier NCT02604966). METHODS: Sixty patients received either dihydroartemisinin/piperaquine (4 mg/kg/day, 3 days; n = 33) or artesunate monotherapy (4 mg/kg/day, 3 days; n = 27) followed by dihydroartemisinin/piperaquine (AS + DHA/PPQ). Clinical phenotypes were determined during a 42 day follow-up and analysed together with ex vivo susceptibility to antimalarials and molecular markers of drug resistance. RESULTS: Day 3 positivity rate was significantly higher in the AS + DHA/PPQ arm compared with dihydroartemisinin/piperaquine (70.4% versus 39.4%, P = 0.016). Parasite clearance time was 95.2 h (AS + DHA/PPQ) versus 71.9 h (dihydroartemisinin/piperaquine, P = 0.063) and parasite clearance half-life was 7.4 h (AS + DHA/PPQ) versus 7.0 h (dihydroartemisinin/piperaquine, P = 0.140). Adequate clinical and parasitological response at Day 42 was 100% in both arms. By RT-qPCR, 36% (19/53) patients remained positive until Day 7. No recurrences were detected. kelch13 artemisinin resistance mutations were found in 87% (39/45) of isolates and 50% (20/40) were KEL1/C580Y. The piperaquine resistance marker plasmepsin-2 was duplicated in 10.4% (5/48). Isolates from Day 3-positive patients (n = 18) had higher ex vivo survival rates to artemisinin compounds (P < 0.048) and prevalence of kelch13 mutations (P = 0.005) than Day 3-negative patients (n = 5). The WHO definition of artemisinin resistance was fulfilled in 60% (24/40) of cases. CONCLUSIONS: Although dihydroartemisinin/piperaquine remained effective to treat P. falciparum, the high Day 3 positivity rate and prevalence of KEL1 strains calls for continuous monitoring of dihydroartemisinin/piperaquine efficacy in Central Vietnam.
Authors: Charles J Woodrow; Sabina Dahlström; Richard Cooksey; Jennifer A Flegg; Hervé Le Nagard; France Mentré; Claribel Murillo; Didier Ménard; François Nosten; Kanlaya Sriprawat; Lise Musset; Neils B Quashie; Pharath Lim; Rick M Fairhurst; Sam L Nsobya; Veronique Sinou; Harald Noedl; Bruno Pradines; Jacob D Johnson; Philippe J Guerin; Carol H Sibley; Jacques Le Bras Journal: Antimicrob Agents Chemother Date: 2013-04-22 Impact factor: 5.191
Authors: Mallika Imwong; Tran T Hien; Nguyen T Thuy-Nhien; Arjen M Dondorp; Nicholas J White Journal: Lancet Infect Dis Date: 2017-10 Impact factor: 25.071
Authors: Ricardo Ataide; Elizabeth A Ashley; Rosanna Powell; Jo-Anne Chan; Michael J Malloy; Katherine O'Flaherty; Eizo Takashima; Christine Langer; Takafumi Tsuboi; Arjen M Dondorp; Nicholas P Day; Mehul Dhorda; Rick M Fairhurst; Pharath Lim; Chanaki Amaratunga; Sasithon Pukrittayakamee; Tran Tinh Hien; Ye Htut; Mayfong Mayxay; M Abul Faiz; James G Beeson; Francois Nosten; Julie A Simpson; Nicholas J White; Freya J I Fowkes Journal: Proc Natl Acad Sci U S A Date: 2017-03-13 Impact factor: 11.205
Authors: Olivo Miotto; Roberto Amato; Elizabeth A Ashley; Bronwyn MacInnis; Jacob Almagro-Garcia; Chanaki Amaratunga; Pharath Lim; Daniel Mead; Samuel O Oyola; Mehul Dhorda; Mallika Imwong; Charles Woodrow; Magnus Manske; Jim Stalker; Eleanor Drury; Susana Campino; Lucas Amenga-Etego; Thuy-Nhien Nguyen Thanh; Hien Tinh Tran; Pascal Ringwald; Delia Bethell; Francois Nosten; Aung Pyae Phyo; Sasithon Pukrittayakamee; Kesinee Chotivanich; Char Meng Chuor; Chea Nguon; Seila Suon; Sokunthea Sreng; Paul N Newton; Mayfong Mayxay; Maniphone Khanthavong; Bouasy Hongvanthong; Ye Htut; Kay Thwe Han; Myat Phone Kyaw; Md Abul Faiz; Caterina I Fanello; Marie Onyamboko; Olugbenga A Mokuolu; Christopher G Jacob; Shannon Takala-Harrison; Christopher V Plowe; Nicholas P Day; Arjen M Dondorp; Chris C A Spencer; Gilean McVean; Rick M Fairhurst; Nicholas J White; Dominic P Kwiatkowski Journal: Nat Genet Date: 2015-01-19 Impact factor: 38.330